和黄医药Sovleplenib治疗温抗体型自身免疫性溶血性贫血新药申请获中国药监局受理并纳入优先审评与突破性治疗品种

美股速递
Apr 29

和黄医药今日宣布,其创新药物Sovleplenib用于治疗温抗体型自身免疫性溶血性贫血的新药申请已获得中国国家药品监督管理局受理,同时被授予优先审评资格与突破性治疗品种认定。这一重要进展标志着该药物在中国商业化进程中迈出关键一步,有望为相关患者提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10